3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
255
Breast Neoplasms
172
Neoplasms
167
Colorectal Neoplasms
154
Neoplasm Metastasis
127
Melanoma
119
Recurrence
116
Prostatic Neoplasms
116
Leukemia, Myeloid, Acute
115
Pancreatic Neoplasms
113
Ovarian Neoplasms
110
Multiple Myeloma
103
Lung Neoplasms
95
Stomach Neoplasms
89
Squamous Cell Carcinoma of Head and Neck
83
Triple Negative Breast Neoplasms
81
Glioblastoma
81
Lymphoma
77
Lymphoma, Non-Hodgkin
75
Lymphoma, Large B-Cell, Diffuse
64
Carcinoma, Renal Cell
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
62
Advanced Solid Tumor
59
Endometrial Neoplasms
58
Carcinoma, Hepatocellular
57
Small Cell Lung Carcinoma
54
Sarcoma
52
Uterine Cervical Neoplasms
51
Myelodysplastic Syndromes
51
Leukemia
49
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
1 year
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled